10X Genomics (TXG)
Up over 84% this past year, 10X Genomics has seen Cathie Wood pick up over $1.8M worth of shares on Monday March 23, 2026 across her ARK series of portfolios. TXG stock currently holds a Buy rating with an average +5% one year forecast according to analyst estimates. On a TTM basis 10X Genomics EPS is still negative but is showing strong momentum and it looks like it’s going to be swinging positive in the next quarter or two – so as far as valuation goes we will have to divert to revenue. With a revenue per share of $5.12 that means TXG has a price to sales of 3.7, which gives it a price to sales/growth (PSG) ratio of just 0.7 at an estimated 5.3% year over year revenue growth estimate. For reference, the S&P500 currently has a PSG ratio of 0.8, meaning TXG is right in line or even slightly undervalued by this metric.
Given this is a Biotech stock this automatically upgrades our risk profile despite TXG beating all 4 of its last earnings calls. We are also seeing insiders loading up on shares right now. So for these reasons in addition to a low PSG ratio; we put 10X Genomics stock a medium risk, high reward stock and give it a Hold rating with a +3.3% one year forecast.
